

ACIP Provisional Recommendations for the Use of Quadrivalent HPV Vaccine

Date of ACIP vote: June 29, 2006

Date of posting of provisional recommendations: August 14, 2006

Tentative date of publication of recommendations in CDC *Morbidity and Mortality Weekly Report*: November 2006

Provisional recommendations for use of quadrivalent HPV vaccine:

- Routine vaccination with three doses of quadrivalent HPV vaccine is recommended for females 11-12 years of age. The vaccination series can be started in females as young as 9 years of age.
- Catch-up vaccination is recommended for females 13-26 years of age who have not been vaccinated previously or who have not completed the full vaccine series. Ideally, vaccine should be administered before potential exposure to HPV through sexual contact.
- Each dose of quadrivalent HPV vaccine is 0.5 mL, administered intramuscularly.
- Quadrivalent HPV vaccine is administered in a three dose schedule. The second and third doses should be administered 2 and 6 months after the first dose.
- Quadrivalent HPV vaccine can be administered at the same visit when other age appropriate vaccines are provided, such as Tdap, Td and MCV4.
- At present, cervical cancer screening recommendations have not changed for females who receive quadrivalent HPV vaccine.

Special situations:

- Quadrivalent HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a positive Hybrid Capture II® high risk test, or genital warts.

Vaccine recipients should be advised that data from clinical trials do not indicate the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital warts. Vaccination of these females would provide protection against infection with vaccine HPV types not already acquired.

- Lactating women can receive quadrivalent HPV vaccine
- Females who are immunocompromised either from disease or medication can receive quadrivalent HPV vaccine. However the immune response to vaccination and vaccine effectiveness might be less than in females who are immunocompetent.

Pregnancy:

- Quadrivalent HPV vaccine is not recommended for use in pregnancy.

The vaccine has not been associated causally with adverse outcomes of pregnancy or adverse events to the developing fetus. However, data on vaccination during pregnancy are limited. Any exposure to vaccine during pregnancy should be reported to the vaccine pregnancy registry (1-800-986-8999).

Contraindications to use of vaccine:

- Quadrivalent HPV vaccine is contraindicated for people with a history of immediate hypersensitivity to yeast or to any vaccine component.

Precautions:

- Quadrivalent HPV vaccine can be administered to females with minor acute illnesses (e.g., diarrhea or mild upper respiratory tract infections, with or without fever). Vaccination of people with moderate or severe acute illnesses should be deferred until after the illness improves.